Download PDF
Thromb Haemost 2012; 107(04): 602
DOI: 10.1160/TH12-01-0054
Invited Editorial Focus
Schattauer GmbH

Taking advantage of the non-anticoagulant effects of heparin

Andreas Greinacher
1   Department of Immunology and Transfusion Medicine, Ernst-Moritz-Arndt-University, Greifswald, Germany
› Author Affiliations
Further Information

Publication History

Received: 31 January 2012

Accepted: 31 January 2012

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

 

Editorial on ► Joglekar et al. Thromb Haemost 2012; 107: 717-725.

 

  • References

  • 1 Joglekar MV, Quintana Diez PM, Marcus S. et al. Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thromb Haemost 2012; 107: 717-725.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Atha DH, Lormeau JC, Petitou M. et al. Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistr 1985; 24: 6723-6729.
    CrossrefPubMedGoogle Scholar
  • 3 Krauel K, Hackbarth C, Fürll B. et al. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2011 epub ahead of print.
    PubMedGoogle Scholar
  • 4 Thakur S, Pigott JP, Comerota AJ. Heparin-induced thrombocytopenia after implantation of a heparinbonded polytetrafluoroethylene lower extremity bypass graft: A case report and plan for management. J Vasc Surg 2009; 49: 1037-1040.
    CrossrefPubMedGoogle Scholar
  • 5 Gabrielli R, Siani A, Rosati MS. et al. Heparin-in-duced thrombocytopenia type II because of hepa-rin-coated polytetrafluoroethylene graft used to bypass. Ann Vasc Surg 2011; 25 840 e9-12.
    CrossrefPubMedGoogle Scholar
  • 6 Wheatcroft MD, Greco E, Tse L. et al. Heparin-in-duced thrombocytopenia in the presence of a heparin-bonded bypass graft. Vascular 2011; 19: 338-341.
    CrossrefPubMedGoogle Scholar
  • 7 Greinacher A, Kohlmann T, Strobel U. et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 4970-4976.
    CrossrefPubMedGoogle Scholar
  • 8 Petitou M, Hérault JP, Bernat A. et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999; 398: 417-422.
    CrossrefPubMedGoogle Scholar
  • 9 Greinacher A. Immunogenic but effective: the HIT-fondaparinux brain puzzler. J Thromb Haemost 2011; 09: 2386-2388.
    CrossrefPubMedGoogle Scholar
  • 10 Yau JW, Stafford AR, Liao P. et al. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 2011; 118: 6667-6674.
    CrossrefPubMedGoogle Scholar
  • 11 Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012; 38: 20-28.
    CrossrefPubMedGoogle Scholar